Beyondspring (NASDAQ:BYSI) posted its earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05), Fidelity Earnings reports.
Shares of Beyondspring stock opened at $17.64 on Friday. Beyondspring has a twelve month low of $13.06 and a twelve month high of $26.86. The company’s fifty day moving average is $17.66 and its 200 day moving average is $17.40.
BYSI has been the topic of a number of research reports. Zacks Investment Research cut shares of Beyondspring from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $41.00 target price on shares of Beyondspring in a research note on Wednesday. Finally, ValuEngine cut shares of Beyondspring from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.